{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 12,
  "pageCount": 29,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "data_table",
  "function": "quantify_impact",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "kpi_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/12",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "metric",
      "text": "Clinical trial endpoints",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a620-ae02e7aefbf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.86,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "table",
      "text": "DAVIO2 Endpoint, 2mg, 3mg, Primary: Non-inferior change in BCVA vs. aflibercept, - 0.3 letters, - 0.4 letters, Secondary: Favorable safety profile, No DURAVYU-related SAEs, Secondary: Reduction in treatment burden vs. 6 mos. prior, 89%, 85%, Secondary: Reduction in treatment burden vs. aflibercept, 82%, 76%, Secondary: Supplement-free up to 6 months, 63% (88% of eyes had 0 or 1 supplemental injections), 63% (83% of eyes had 0 or 1 supplemental injections), Secondary: Anatomical control vs. aflibercept, +12.4um, +5.2um",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ed0329a-6159-48ab-8199-aec136a22f83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Ongoing DURAVYU Phase 3 Trials in Wet AMD Supported by Phase 2 DAVIO 2 Results - All Primary and Secondary Endpoints Met",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17b534d3-9fd9-4102-909a-4e6d81c7b88b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}